Table 2.
The 100 most-cited articles from the Journal of CAR-T.
| Title | Journal | Published year | Total citation (n) |
|---|---|---|---|
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Science Translational Medicine | 2011 | 1,189 |
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial | Lancet | 2015 | 1,175 |
| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Science Translational Medicine | 2014 | 1,102 |
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an Anti-CD19 chimeric antigen receptor | Journal of Clinical Oncology | 2015 | 772 |
| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma | New England Journal of Medicine | 2017 | 728 |
| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia | New England Journal of Medicine | 2018 | 722 |
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Science Translational Medicine | 2015 | 629 |
| CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients | Journal of Clinical Investigation | 2016 | 579 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients | Journal of Clinical Investigation | 2011 | 568 |
| Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma | Blood | 2011 | 536 |
| Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia | New England Journal of Medicine | 2018 | 426 |
| 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors | Nature Medicine | 2015 | 406 |
| Regression of glioblastoma after chimeric antigen receptor T-cell therapy | New England Journal of Medicine | 2016 | 398 |
| CAR T cell immunotherapy for human cancer | Science | 2018 | 373 |
| Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumor rejection | Nature | 2017 | 372 |
| Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies | Cancer Immunology Research | 2014 | 372 |
| Antibody-modified T cells: CARs take the front seat for hematologic malignancies | Blood | 2014 | 363 |
| Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma | Journal of Clinical Oncology | 2015 | 358 |
| The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Nature Reviews Clinical Oncology | 2016 | 351 |
| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 349 |
| Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8(+) and CD4(+) CD19-specific chimeric antigen receptor-modified T cells | Science Translational Medicine | 2016 | 338 |
| Toxicities of chimeric antigen receptor T cells: recognition and management | Blood | 2016 | 327 |
| Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells | Clinical Cancer Research | 2013 | 323 |
| Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity | Molecular Therapy | 2013 | 308 |
| Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells | Science Translational Medicine | 2012 | 308 |
| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation | Blood | 2013 | 304 |
| CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia | Blood | 2015 | 299 |
| The principles of engineering immune cells to treat cancer | Cell | 2017 | 296 |
| Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning | Blood | 2012 | 296 |
| Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells | Science Translational Medicine | 2017 | 288 |
| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma | Science Translational Medicine | 2017 | 280 |
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy | Nature Medicine | 2018 | 270 |
| Chimeric antigen receptor therapy | New England Journal of Medicine | 2018 | 264 |
| Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia | Cancer Discovery | 2016 | 256 |
| T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma | Blood | 2016 | 246 |
| Toxicity and management in CAR T-cell therapy | Molecular Therapy—Oncolytics | 2016 | 246 |
| T cells expressing chimeric antigen receptors can cause anaphylaxis in humans | Cancer Immunology Research | 2013 | 246 |
| Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition | Journal of Clinical Investigation | 2016 | 241 |
| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma | New England Journal of Medicine | 2019 | 235 |
| Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor | Cancer Research | 2010 | 235 |
| Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells | Immunity | 2016 | 234 |
| Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors | Nature Reviews Clinical Oncology | 2013 | 233 |
| Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells | Cancer Discovery | 2017 | 229 |
| Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo | Leukemia | 2016 | 227 |
| Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults | Blood | 2017 | 222 |
| Allogeneic t cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-vs.-host disease | Journal of Clinical Oncology | 2016 | 217 |
| Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition | Clinical Cancer Research | 2017 | 216 |
| Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells | Cancer Cell | 2015 | 216 |
| Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor | Clinical Cancer Research | 2011 | 216 |
| Design and development of therapies using chimeric antigen receptor-expressing T cells | Immunological Reviews | 2014 | 213 |
| Driving CAR T-cells forward | Nature Reviews Clinical Oncology | 2016 | 208 |
| Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy | Blood | 2016 | 207 |
| A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR | Blood | 2012 | 206 |
| Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells | Clinical Cancer Research | 2013 | 203 |
| Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor | Blood | 2010 | 197 |
| Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma | Molecular Therapy | 2017 | 196 |
| Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma | Science Translational Medicine | 2015 | 193 |
| Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 | Blood | 2014 | 190 |
| Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia | Molecular Therapy | 2013 | 188 |
| Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity | Science Translational Medicine | 2014 | 187 |
| Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes | Nature Medicine | 2015 | 183 |
| Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies | Immunological Reviews | 2015 | 181 |
| Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells | Blood | 2011 | 181 |
| Cancer immunotherapy: harnessing the immune system to battle cancer | Journal of Clinical Investigation | 2015 | 180 |
| Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells | Nature Medicine | 2018 | 179 |
| Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia | Nature Medicine | 2018 | 177 |
| T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia | Blood | 2013 | 177 |
| The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity | Cancer Immunology Research | 2015 | 175 |
| Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy | Blood | 2017 | 174 |
| Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells | Journal of Clinical Investigation | 2016 | 174 |
| Multiplex genome-edited T-cell Manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies | Cancer Research | 2015 | 174 |
| Tandem CAR T cells targeting HER2 and IL13R alpha 2 mitigate tumor antigen escape | Journal of Clinical Investigation | 2016 | 170 |
| IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression | Cancer Research | 2011 | 170 |
| Redirecting specificity of T-cell populations for CD19 using the Sleeping beauty system | Cancer Research | 2008 | 169 |
| Durable Molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib | Journal of Clinical Oncology | 2017 | 164 |
| Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma | Immunity | 2016 | 164 |
| T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells | Cancer Immunology Research | 2016 | 162 |
| In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) | Cancer Research | 2011 | 161 |
| Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors | Clinical Cancer Research | 2014 | 159 |
| Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma | Human Gene Therapy | 2012 | 157 |
| CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade | Nature Medicine | 2018 | 155 |
| A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors | Cancer Research | 2016 | 151 |
| CD27 co-stimulation augments the survival and antitumor activity of redirected human T cells in vivo | Blood | 2012 | 151 |
| Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice | Cancer Research | 2015 | 149 |
| Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity | Cancer Immunology Research | 2014 | 147 |
| CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date | Blood | 2016 | 145 |
| CAR T cell therapy for solid tumors | NA | 2017 | 144 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia | Blood | 2016 | 142 |
| Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo | Cancer Immunology Research | 2013 | 142 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial | Lancet Oncology | 2019 | 141 |
| Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity | Cancer Research | 2015 | 136 |
| Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells | Cancer Research | 2015 | 134 |
| Global manufacturing of CAR T cell therapy | Molecular Therapy-Methods & Clinical Development | 2017 | 133 |
| Mesothelin-targeted CARs: driving T cells to solid tumors | Cancer Discovery | 2016 | 133 |
| Novel immunotherapies in lymphoid malignancies | Nature Reviews Clinical Oncology | 2016 | 131 |
| Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA(+) liver metastases | Clinical Cancer Research | 2015 | 131 |
| Chimeric antigen receptor T-cell therapies for lymphoma | Nature Reviews Clinical Oncology | 2018 | 130 |
| Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies | Proceedings of the National Academy of Sciences of the United States of America | 2016 | 129 |
| CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells | Scientific Reports | 2017 | 128 |
| ICOS-based chimeric antigen receptors program bipolar T(H)17/T(H)1 cells | Blood | 2014 | 127 |